David D Stern

US Patent:

6391300, May 21, 2002

Filed:

Nov 16, 1998

Appl. No.:

09/192905

Inventors:

Eric Rose - Tenafly NJ
David Stern - Great Neck NY
Ann Marie Schmidt - Franklin Lakes NJ
Talia Spanier - New York NY

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

A61K 3836

US Classification:

4241451, 424 9464, 4241581, 435226, 514 2, 514 12, 530381

Abstract:

This invention provides a method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal blood circulation which comprises contacting the extracorporeal circulating blood with a Factor IXa compound in an amount effective to inhibit thrombosis in the blood of a patient and under conditions such that the Factor IXa compound circulates in the patient. The Factor IXa compound may include an active site-blocked Factor IXa compound or Glu-Gly-Arg chloromethyl ketone-inactivated human factor IXa compound. This invention also provides that the effective amount may be from about 0. 1 g/ml plasma to about 250 g/ml plasma or from about 0. 5 g/ml plasma to about 25 g/ml plasma. The patient may be subjected to extracorporeal blood circulation during transplant surgery or cardiopulmonary bypass surgery. This invention further provides for a method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal blood circulation, which comprises contacting the extracorporeal circulating blood with an agent capable of inhibiting a step of the intrinsic pathway of coagulation in an amount effective to inhibit thrombosis in the blood of a patient and under conditions such that the Factor IXa compound circulates in the patient.

US Patent:

6555651, Apr 29, 2003

Filed:

Oct 9, 1997

Appl. No.:

08/948131

Inventors:

David Stern - Great Neck NY
Shi Du Yan - New York NY
Ann Marie Schmidt - Franklin Lakes NJ
Ira Lamster - Wyckoff NJ

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

A61K 3800

US Classification:

530324, 530300

Abstract:

The present method provides for an isolated peptide having an amino acid sequence corresponding to the amino acid sequence of a V-domain of a receptor for advanced glycation endproduct (RAGE). The present invention also provides for an isolated peptide having an amino acid sequence A-Q-N-I-T-A-R-I-G-E-P-L-V-L-K-C-K-G-A-P-K-K-P-P-Q-R-L-E-W-K (SEQ. ID No: 1). The present invention provides for a pharmaceutical composition comprising a therapeutically effect amount of an isolated peptide having an amino acid sequence corresponding to the amino acid sequence of a V-domain of RAGE. The present invention also provides for a method for inhibiting interaction of an amyloid- peptide with a receptor for advanced glycation end product which is on the surface of a cell, which comprises contacting the cell with the peptide or a functionally equivalent agent, wherein the peptide or agent is capable of inhibiting interaction of the amyloid- peptide with the receptor for advanced glycation end product, and the peptide or agent is present in an amount effective to inhibit interaction of the amyloid- peptide with the receptor for advanced glycation endproduct.

US Patent:

6563015, May 13, 2003

Filed:

Aug 14, 2000

Appl. No.:

09/638649

Inventors:

David M. Stern - Great Neck NY
Ann Marie Schmidt - Franklin Lakes NJ
Shi Du Yan - New York NY

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

G01N 3300

US Classification:

800 3, 800 12, 800 18

Abstract:

The invention provides for a non-human transgenic animal whose cells contain a recombinant DNA sequence comprising: (a) a nerve tissue specific promoter operatively linked to a DNA sequence which encodes human receptor for advanced glycation endproducts (RAGE), and (b) a nerve tissue specific promoter operatively linked to a DNA sequence encoding a mutant human amyloid precursor protein hAPP695, hAPP751 and hAPP770 bearing mutations linked to familial Alzheimers disease in humans, wherein said non-human transgenic animal exhibits at least one phenotype from the group consisting of: increased expression of M-CSF gene in cerebral cortex; increased expression of IL-6 gene in cerebral cortex; increased neuronal stress; increased neurotoxicity; neuron loss; increased level of activated form of caspase 3 in brain; and increased level of phosphorylated tau protein in brain.

US Patent:

6677299, Jan 13, 2004

Filed:

Nov 5, 2001

Appl. No.:

09/992955

Inventors:

David M. Stern - Great Neck NY
Ann Marie Schmidt - Franklin Lakes NJ
Shi Du Yan - New York NY
Berislav Zlokovic - Rochester NY

Assignee:

The Trustee of Columbia University in the city of New York - New York NY

International Classification:

A01N 6100

US Classification:

514 1, 514 2, 514 44, 800 3, 800 8, 800 9, 800 12, 800 13, 800 18

Abstract:

The present invention provides a method for decreasing cerebral vasoconstriction in a subject suffering from chronic or acute cerebral amyloid angiopathy which comprises administering to the subject an inhibitor of receptor for advanced glycation endproduct (RAGE) in an effective amount to inhibit transcytosis of amyloid peptides across the blood-brain barrier in the subject, thereby decreasing cerebral vasoconstriction in the subject. The invention further provides for a method for ameliorating neurovascular stress in a subject which comprises administering to the subject an effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE), so as to increase cerebral blood flow in the subject, thereby ameliorating neurovascular stress in the subject.

US Patent:

6734168, May 11, 2004

Filed:

May 7, 2001

Appl. No.:

09/851026

Inventors:

David M. Stern - Great Neck NY
Matthias Clauss - Bad Nauheim, DE
Janet Kao - New York NY
Mark Kayton - New York NY
Steven K. Libutti - Fort Lee NJ

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

A61K 3800

US Classification:

514 12, 514 13

Abstract:

The present invention provides for a purified endothelial monocyte activating polypeptide II, wherein the polypeptide has an apparent molecular weight of about 20,000 Daltons. The present invention also provides for an effector cell activating protein comprising a polypeptide having an amino acid sequence wherein at least four amino acid residues are the same as RIGRTVT and are in the same relative positions. The invention also provides for a DNA which encodes the effector cell activating protein. The invention also provides for methods of inducing inflammation in a subject and methods of treating tumors in a subject. The invention also provides for a pharmaceutical composition which comprises the endothelial monocyte activating polypeptide II and a carrier.

US Patent:

6790443, Sep 14, 2004

Filed:

Nov 22, 1996

Appl. No.:

08/755235

Inventors:

David M. Stern - Great Neck NY
Ann Marie Schmidt - Franklin Lakes NJ

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

A61K 39395

US Classification:

4241301, 4241581, 4241841, 4242781, 435325, 435334, 435440, 514 2, 530350, 53038822

Abstract:

The present invention provides a method for treating symptoms of diabetes in a diabetic subject which comprises administering to the subject a therapeutically effective amount of an agent which inhibits binding of advanced glycation endproducts to any receptor for advanced glycation endproducts so as to treat chronic symptoms of diabetes in the subject.

US Patent:

6825164, Nov 30, 2004

Filed:

Aug 14, 2000

Appl. No.:

09/638648

Inventors:

David M. Stern - Great Neck NY
Ann Marie Schmidt - Franklin Lakes NJ
Shi Du Yan - New York NY
Berislav Zlokovic - Rochester NY

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

A01N 6100

US Classification:

514 1, 514 2, 514 44, 800 3, 5303871

Abstract:

The present invention provides a method for decreasing cerebral vasoconstriction in a subject suffering from chronic or acute cerebral amyloid angiopathy which comprises administering to the subject an inhibitor of receptor for advanced glycation endproduct (RAGE) in an effective amount to inhibit transcytosis of amyloid peptides across the blood-brain barrier in the subject, thereby decreasing cerebral vasoconstriction in the subject. The invention further provides for a method for ameliorating neurovascular stress in a subject which comprises administering to the subject an effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE), so as to increase cerebral blood flow in the subject, thereby ameliorating neurovascular stress in the subject.

US Patent:

6891081, May 10, 2005

Filed:

Aug 14, 2000

Appl. No.:

09/638695

Inventors:

David M. Stern - Great Neck NY, US
Shi Du Yan - New York NY, US

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

A01K067/00
A01K067/027
G01N033/00
C12N015/00
C12N005/00

US Classification:

800 12, 800 3, 800 8, 800 9, 800 13, 800 18, 435455, 435463, 4353201, 435325

Abstract:

The present invention provides for a transgenic non-human animal whose cells contain a recombinant DNA sequence comprising a nerve tissue specific promoter operatively linked to a DNA sequence which encodes amyloid-beta peptide alcohol dehydrogenase (ABAD), and exhibits at least one phenotype from the group consisting of: overexpression of ABAD, elevated levels of basal ATP; protection from metabolic or ischemic stress.

Address:

250 Central Ave APT D220, Lawrence, NY 11559

VIN:

1GYFK63847R305333

Make:

CADILLAC

Model:

ESCALADE

Year:

2007